KATHRYN EVANS: Open Payments
NPI 1528434214 · GREENWOOD, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,063 in 58 payments from 12 companies in 2025. Trend: 2023 $942 · 2024 $1,055 · 2025 $1,063
Food & beverage: $1,063
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $276 |
| Madrigal Pharmaceuticals | 10 | $217 |
| Janssen Biotech, Inc. | 9 | $182 |
| Ardelyx, Inc. | 8 | $149 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $60 |
| Octapharma USA, Inc. | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Aimmune Therapeutics, Inc. | 1 | $24 |
| QOL Medical, LLC | 1 | $23 |
| Novo Nordisk Inc | 1 | $19 |
Products named: REZDIFFRA, TREMFYA, IBSRELA, CREON, VIBERZI, XIFAXAN, PANZYGA, RINVOQ.
Industry payments across MS — which companies pay providers there.
